PL Capital believes the company is well positioned to benefit from increasing pharmaceutical outsourcing, a deep commercial pipeline and capacity expansion
Back to Business
Business
October 23, 2026 at 8:50 AM
Already jumped 55% in 2026, PL Capital sees more returns in Sai Lifesciences shares | Check target, upside
Livemint Markets
Excerpt from Livemint Markets.